[Use of botulinum toxin for pain therapy].
Preventive measures are necessary against contraction of botulism through food intake or due to other factors because the botulinum neurotoxin (BoNT) is one of the strongest toxins. Despite this, given its therapeutic utility in the controll of neuromuscular transmission, BoNT has been utilized to treat diseases related to muscular hyperactivity, such as dystonia and spasticity. Furthermore, it has been recognized that BoNT is also useful in controlling the neurotransmitter release of sensory and autonomic nerve terminals as well. This paper reviews the recent progress in the therapeutic use of BoNT in pain management, for example, in condition such as migraine, myofascial pain syndrome, pelvic pain, and interstitial cystitis.
Nodera
Hiroyuki
H
Department of Neurology, Tokushima University, 2-50-1 Kuramoto-cho, Tokushima-shi, Tokushima 770-8503, Japan.
D000818:Animals; D017776:Autonomic Pathways / Q000378:metabolism; D001905:Botulinum Toxins / Q000008:administration & dosage* / Q000494:pharmacology; D018856:Cystitis, Interstitial / Q000188:drug therapy; D003864:Depression, Chemical; D005157:Facial Pain / Q000188:drug therapy; D005724:Ganglia / Q000378:metabolism; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy; D009437:Neuralgia / Q000188:drug therapy*; D009479:Neuropeptides / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism; D017699:Pelvic Pain / Q000188:drug therapy; D050600:SNARE Proteins / Q000378:metabolism; D011984:Sensory Receptor Cells / Q000378:metabolism; D050916:TRPV Cation Channels / Q000378:metabolism
D009479:Neuropeptides; D018377:Neurotransmitter Agents; D050600:SNARE Proteins; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D001905:Botulinum Toxins